POPULARITY
Categories
162 episodes with O2
76 episodes with O2
48 episodes with O2
46 episodes with O2
27 episodes with O2
33 episodes with O2
47 episodes with O2
40 episodes with O2
45 episodes with O2
20 episodes with O2
15 episodes with O2
16 episodes with O2
14 episodes with O2
20 episodes with O2
8 episodes with O2
8 episodes with O2
12 episodes with O2
7 episodes with O2
6 episodes with O2
9 episodes with O2
8 episodes with O2
7 episodes with O2
43 episodes with O2
5 episodes with O2
4 episodes with O2
9 episodes with O2
14 episodes with O2
5 episodes with O2
8 episodes with O2
6 episodes with O2
5 episodes with O2
5 episodes with O2
6 episodes with O2
6 episodes with O2
5 episodes with O2
6 episodes with O2
6 episodes with O2
6 episodes with O2
5 episodes with O2
10 episodes with O2
5 episodes with O2
10 episodes with O2
4 episodes with O2
5 episodes with O2
4 episodes with O2
5 episodes with O2
6 episodes with O2
7 episodes with O2
4 episodes with O2
5 episodes with O2
3 episodes with O2
6 episodes with O2
5 episodes with O2
3 episodes with O2
Will Fabio Wardley's stunning stoppage of Joseph Parker set up a showdown with Oleksandr Usyk in 2026? Richie Woodhall joins Buncey to break down a dramatic night at the O2, where Wardley, behind on most scorecards, produced a sensational 10th-round finish. We hear from Wardley himself, plus his manager Dillian Whyte, trainer Ben Davison, and promoter Frank Warren.
Hostem Pressklubu Frekvence 1 byla sportovní ředitelka Global Champions Prague Playoffs Markéta Šveňková. Ondřej Kopa si s ní povídal o přípravách mezinárodních parkurových závodů, které se v pražské O2 aréně uskuteční od 20. listopadu. Podle ředitelky soutěže nás čeká vrchol nejprestižnějšího parkurového závodu světa. Poslechněte si podrobnosti o soutěži v záznamu pořadu.See omnystudio.com/listener for privacy information.
Will Joseph Parker's experience and composure prove decisive, or will Fabio Wardley's raw power and knockout instinct prove too much? Buncey is in London ahead of Saturday's huge heavyweight clash at the O2, catching up with promoter Frank Warren, hearing from both camps, and getting the thoughts of Wardley himself as well as Parker's manager, Spencer Brown.You can hear commentary of the fight on 5 Live and BBC Sounds from 10pm Saturday night.
Buenos días, Javi y Mar presenta noticias sobre conflictos de atribuciones en España, la situación de Sarkozy en prisión y la reapertura del Louvre. Lola Young y Paolo Nutini musicalizan el programa. Los oyentes comparten anécdotas de haber quedado atrapados y se debate sobre el "síndrome de la oreja de Van Gogh", relacionado con relaciones pasadas y la importancia de las segundas oportunidades, invitando a los oyentes a compartir sus experiencias. También se promueve O2, Codis, Peugeot, Movistar Prosegur Alarmas, Repsol y el Ministerio de Cultura. The Weeknd y Ed Sheeran ponen la música. Se juega "Al pie de la letra" con un oyente, Samuel, quien responde preguntas con la letra 'N'. Continúan las llamadas de oyentes, incluyendo la historia de Juli sobre su MRI y David sobre un incidente en un embalse. Katy Perry y Adele musicalizan la mañana. CADENA 100, desde Castellón, habla de cómo las escuelas lucen limpias gracias al personal de limpieza. Se pregunta a los niños por qué se cambia ...
Když Tatiana Dyková tančila téměř před dvaceti lety poprvé ve StarDance, byla těhotná – a nikdo to nevěděl. Letos se na parket vrátila, tentokrát na velkolepé StarDance tour, která zaplnila i pražskou O2 arénu. Jaké to je být znovu pod drobnohledem, kdy se místo tance řeší vlasy, šaty a věk? A proč se o Tatianě pořád píše, že je arogantní – když je možná jen upřímná? V otevřeném rozhovoru pro Kavky 2.0 mluví o tom, jak zvládá tlak bulváru, o vztahu s manželem Vojtěchem Dykem, o dětech, herecké rivalitě i o tom, proč si z branže dělá legraci, aby ji přežila. Dozvíte se, jak vypadá StarDance za oponou, co ji nejvíc štve na mediálním obrazu žen, proč by všem ezoterikům doporučila pořídit si děti – a jak se utírá realita, když člověk hraje, tančí a zároveň vychovává tři syny.Tatiana Dyková bez filtru. O Stardance, slávě, mateřství i o tom, proč občas není špatné být za mrchu.
Dnes za námi dorazila skupina Lucie ve složení Robert Kodym, Michal Dvořák a Štěpán Smetáček. Už 8. listopadu jim odstartuje podzimní turné, které si „rozehráli“ už takzvaným warm-upem v Londýně – a místo jednoho koncertu tam odehráli rovnou dva. V rozhovoru s Lubkou a Mírou mluvili o svých londýnských fanoušcích, chystaném turné a hlavně o tom, co připravují na velké koncerty v O2 areně – včetně překvapivých hostů, na které se fanoušci mohou těšit. Poslechněte si celý rozhovor!See omnystudio.com/listener for privacy information.
We take a closer look at the online world known as the manosphere—a loose network of communities including incels, Men Going Their Own Way (MGTOW), men's rights activists (MRAs), and pick-up artists (PUAs).These groups may look different on the surface, but they share a common core: resentment toward feminism, nostalgia for traditional masculinity, and a belief that men are the new victims of modern society. With guidance from researcher Havana Mohr-Ramirez, we unpack how these subcultures operate, where they overlap, and why they've become such powerful forces in shaping how young men see themselves and their place in the world.Drawing on insights from Laura Bates, author of Men Who Hate Women, and sociologist Ellis Cashmore, the episode examines whether the manosphere is an organized movement or something more elusive that still influences real attitudes, politics, and violence.This documentary episode goes beyond headlines and outrage to ask deeper questions about identity, belonging, and what happens when online spaces built around grievance start reshaping the world outside the screen.Text me your feedback and leave your contact info if you'd like a reply (this is a one-way text). Thanks, DavidUp The Middle PromoSupport the showShow Notes:https://outrageoverload.net/ Follow me, David Beckemeyer, on Twitter @mrblog or email outrageoverload@gmail.com. Follow the show on Twitter @OutrageOverload or Instagram @OutrageOverload. We are also on Facebook /OutrageOverload.HOTLINE: 925-552-7885Got a Question, comment or just thoughts you'd like to share? Call the O2 hotline and leave a message and you could be featured in an upcoming episodeIf you would like to help the show, you can contribute here. Tell everyone you know about the show. That's the best way to support it.Rate and Review the show on Podchaser: https://www.podchaser.com/OutrageOverload Intro music and outro music by Michael Ramir C.Many thanks to my co-editor and co-director, Austin Chen.
YA NO SÉ NI LO QUE DIGO. - El nuevo show de Ignasi Taltavull en Youtube https://bit.ly/IgnasiYT y en Spotify https://bit.ly/IgnasiSpotify La Ruina desde Madrid con Ignasi Taltavull (@ignasitf), Tomàs Fuentes (@cap0) y Pantomima Full, con Alberto Casado gestionando a los fans enfadados de Luis Miguel y Rober Bodegas no sabiendo ver las indirectas. El juego, la taza y todo el merchandising oficial de La Ruina en https://lallamastore.com/ Este episodio cuenta con la colaboración de O2, la compañía de fibra y móvil. +info en https://o2online.es Ignasi Taltavull: http://www.instagram.com/ignasitf Tomàs Fuentes http://www.twitter.com/cap0 http://www.instagram.com/cap0 La Ruina sigue en redes: @laruinashow http://www.instagram.com/laruinashow
In what most likely will be the last primary rock n' roll installment before I slow down production for a while, we hopscotch through a ton my favorite bands. This was a two hour episode that I spent all weekend on basically. I did take a two hour break to trot over to the local comedy club tonight to catch Doug Stanhope while he was in town. That show definitely did not disappoint and now it's midnight before a work day and here I am, still piled up in front of this computer chomping away at my keyboard for you, my loyal listening populous. My favorite portions of this episode would be No Quarter live at the O2, The Ramsey Trio-Doobie Bros-LRB run in the middle of the episode is on fire and of course I am biased about the Jai Paul Coachella set. So what. I will be here foundling around and publishing another wicked hot installment next weekend, my birthday weekend so I'm sure it'll be a super sick banger. Until then..Your fav internet disc jockey,Witwicka Juan Don
Today on the show we talk to Joseph Parker who's fighting Fabian Wardley in the O2 arena on the 25th of October. We talk about the fight, Derek Chisora and how life is going with the big man.
Review the indications for oxygen administration and monitoring O2 saturation with pulse oximetry for patients in various ACLS algorithms.The O in MONA is Oxygen.When we should administer oxygen to ACS patients.When O2 administration is unnecessary based on an accurate pulse ox.Monitoring patient's oxygen saturation (SaO2) using a pulse oximeter.Review two common ACLS pre-arrest mega code scenarios.Oxygen administration during CPR and post cardiac arrest.You can find additional medical podcasts that cover ACLS-related topics, on the Pod Resources page at PassACLS.com**American Cancer Society (ACS) Fundraiser This is the seventh year that I'm participating in Men Wear Pink to increase breast cancer awareness and raise money for the American Cancer Society's life-saving mission.I hope you'll consider contributing.Every donation makes a difference in the fight against breast cancer! Paul Taylor's ACS Fundraiser Page: http://main.acsevents.org/goto/paultaylorTHANK YOU for your support! Good luck with your ACLS class!Links: Buy Me a Coffee at https://buymeacoffee.com/paultaylor Free Prescription Discount Card - Get your free drug discount card to save money on prescription medications for you and your pets: https://safemeds.vip/savePass ACLS Web Site - Other ACLS-related resources: https://passacls.com@Pass-ACLS-Podcast on LinkedIn Check out ConveyMed.io for more free online medical education (FOAMed) opportunities.
En los confines de Europa se extiende un mar enclaustrado que durante siglos ha sido zona de choque entre potencias y hoy vuelve a estar en el centro del tablero geopolítico. Desde las ambiciones imperiales de Rusia por acceder al Mediterráneo hasta su papel clave en la guerra de Ucrania, el mar Negro ha sido escenario de conflictos, bloqueos navales y luchas por el control de recursos estratégicos. Sus aguas conectan Europa del Este con el Cáucaso, y por ellas transitan hidrocarburos vitales para el continente y cereales que alimentan a millones de personas en África y Oriente Medio. La Convención de Montreux regula desde hace casi un siglo quién puede navegar por sus estrechos, convirtiendo a Turquía en guardián de una de las puertas más estratégicas del planeta. Hoy en "No es el fin del mundo" hablamos de la geopolítica del mar Negro. Mapas proyectados: Mapa geopolítica del mar Negro: https://elordenmundial.com/mapas-y-graficos/mapa-geopolitica-mar-negro/ Mapa de expansión del Imperio ruso: https://elordenmundial.com/mapas-y-graficos/mapa-expansion-imperio-ruso/ Mapa de la Guerra Fría en Europa: https://elordenmundial.com/mapas-y-graficos/europa-telon-de-acero/ Libros recomendados: "Estambul" y "El libro negro", de Orhan Pamuk Este episodio cuenta con una mención publicitaria de O2. Para ir a nuestro directo en valencia el 28 de octubre apúntate aquí: https://innovacion.upv.es/es/evento/la-nueva-geopolitica-de-la-investigacion/
Some of the IMA's most successful Insight leaders have gone one step further, and estimated the value that the Insight team itself has added each year, ultimately expressing this as a return on Insight investment.In today's episode, James talks to two senior UK Insight leaders, Danny Russell (ex Sky and O2) and Suzanne Lugthart (formerly with ebay, ITV and Rightmove). They have just launched a new initiative called Bigger Than Biscuits that aims to catalogue some great examples of how Insight, research and analysis have added value to business decisions.Has your research led to a successful advertising campaign? Has your analysis led to cost savings or increased revenue by relocating stores or the way products are displayed in them? Has your joined-up insight helped reshape company strategy and unlocked hidden growth opportunities?If it has, your work could be an invaluable addition to this initiative and help other Insight professionals make the case for greater investment in Insight. Please listen to find out more! Topics DiscussedIntroducing Bigger Than Biscuits (2.56)Are CMOs spending less on market research? (6.59)Insight as a cost or investment? (10.20)Think commercially and keep a value log (14.02)It's all about estimation (17.42)The ECB's Hundred £1bn valuation (22.33)It starts with prioritisation (25.43)How to get involved (27.21)A challenge for all listeners (30.30) Highlights“It's the stuff that feeds the innovation pipeline. It's the stuff that feeds the creative platform development. It's all the work we do. I mean it's even stuff like customer experience research. It's anything that can help us diagnose a problem in a business so they can go and do something that will put it all right.” (04:46)“So those stories are there, but people just need the courage to let us work with them to get them out there. The point is that we have to assume that these very important stakeholders around the business let's call it nicely don't really understand and let's be realistic and say they don't really care about the incredible work that we're doing or the stresses that we're under, or the budgetary constraints, etc.” (17.19)“We'd go along and say, okay, you want our time and our budget, so tell me about this thing you're working on, how much money is it going to make and how much are we going to make a difference? And some of them hadn't really thought through and it was good for them to go back, and then they felt they were in this competition for our time and attention and suddenly you feel really quite elevated.” (24.46)“It's about being loud and proud, and if people are still too nervous about that, then just get onto LinkedIn and give us a follow on Bigger Than Biscuits, because that will at least mean they start to see the sort of work that we're doing. .” (29.41) This is episode 79 of the Transforming Insight podcast. If you have the ambition to transform your Insight team and the role it plays in your organisation, please tune in to future episodes. Not only will we explore the secrets of successful corporate Insight teams and their leaders, as outlined in James Wycherley's books, Transforming Insight and The Insight Leader's Playbook, we will also talk to senior corporate Insight leaders, delve into books that have inspired us, and discuss new best practice research carried out with the IMA's corporate members.You won't want to miss this! So please subscribe - and thank you for listening. About James Wycherley, the author of Transforming InsightJames Wycherley was Director of Customer Insight and Analytics at Barclays Bank from 2005 to 2015 when he became Chief Executive of the Insight Management Academy (IMA). He published his first book, Transforming Insight, in 2020, and his second, The Insight Leader's Playbook, in 2025, and he hosts the Insight forums and the Transforming Insight podcast.An entertaining keynote speaker, he has presented over 50 times at Quirk's events, a global record, and has provided thought leadership in the UK, USA, Europe, Canada, Australia, India and the Middle East.The Insight Management Academy is the world's leading authority on transforming corporate Insight teams, and its vision is to inspire and support every Insight leader to transform the impact of Insight in their organisation. Resources:If you would like more information on any of the ideas discussed in this episode of the Transforming Insight podcast, please visit www.insight-management.org DisclaimerThe Transforming Insight podcast is published by the Insight Management Academy and produced by Zorbiant.All rights reserved.
Why Talking Isn't Enough to Bridge DividesWhat happens when people in deeply divided communities set aside differences to work on real problems together? In this episode, we hear from participants in Southern Oregon and from Urban Rural Action's Senior Director of Programs about how building trust and taking action can bridge divides, create belonging, and spark lasting change.Text me your feedback and leave your contact info if you'd like a reply (this is a one-way text). Thanks, DavidKoyoti Small Business PodcastSupport the showShow Notes:https://outrageoverload.net/ Follow me, David Beckemeyer, on Twitter @mrblog or email outrageoverload@gmail.com. Follow the show on Twitter @OutrageOverload or Instagram @OutrageOverload. We are also on Facebook /OutrageOverload.HOTLINE: 925-552-7885Got a Question, comment or just thoughts you'd like to share? Call the O2 hotline and leave a message and you could be featured in an upcoming episodeIf you would like to help the show, you can contribute here. Tell everyone you know about the show. That's the best way to support it.Rate and Review the show on Podchaser: https://www.podchaser.com/OutrageOverload Intro music and outro music by Michael Ramir C.Many thanks to my co-editor and co-director, Austin Chen.
I denne episoden tar vi deg med inn i et favoritthack – rebounding, eller trening på minitrampoline! Dette er noe vi gjør hver eneste dag, både hjemme og sammen med deltakerne på Core Balance. Her deler vi hvorfor denne lekne og enkle treningsformen er så effektiv for lymfehelse, energi, humør og avgiftning – og hvordan du kan komme i gang. Gjennom episoden lærer du hvordan lymfen er kroppens rensesystem, hvorfor den trenger bevegelse for å flyte, og hvorfor noen minutters hopping kan gjøre mer for energien din enn en lang løpetur.Dette lærer du i episoden:Hva lymfesystemet er og hvorfor det er helt avgjørende for immunforsvar og energi?Hvordan trampolinetrening kan øke lymfesirkulasjonen opptil tre ganger mer enn vanlig gange?Hva NASA fant ut om hvorfor rebounding er den mest effektive treningsformen for astronauter?Hvordan opp og ned-bevegelsen fungerer som en “indre dusj” som skyller kroppen ren for avfallsstoffer?Hvorfor rebounding er skånsomt for leddene, men likevel styrker muskler, balanse og kondisjon?Den mentale effekten, hvorfor hopping gjør deg lykkeligere, roligere og mer tilstede?Hvordan du kan starte med bare 5–10 minutter om dagen?Hva slags trampoline du bør velge, og hvorfor bungee-strikker er gullstandarden?Hvordan rebounding faktisk kan styrke bekkenbunnen, ikke svekke den?Hvorfor dette er en biohack for alle, uansett alder, form og nivå?Studier: Mukherjee, A. et al., Entrainment of Lymphatic Contraction to Oscillatory Flow, 2019. Kunert, C. et al., Mechanobiological oscillators control lymph flow, PNAS, 2015. Breslin, J.W., Mechanical forces and lymphatic transport, 2014 (review). Bhattacharya, A. et al., Body acceleration distribution and O2 uptake in humans... (NASA report / J Appl Physiol, 1980). Cugusi, L. et al., Effectiveness of a mini-trampoline rebounding exercise program... (2018). Posch, M. et al., Mini-trampoline training program on balance and mobility... (2019). (se tidligere søk / balansestudier).Trampoline: https://www.jumpsport.com/collections/shop-allnorske nettsider, ser bra ut men vi har ikke testet disse:https://ninefit.no/products/newan-40-silent-fitness-mini-trampoline-indoor-rebounder-for-adults-best-urban-cardio-jump-fitness-workout-trainer-covered-bungee-rope-system-max-limit-330-lbs?gad_source=1&gad_campaignid=17181672367https://www.fitshop.no/cardiojump-fitnesstrampoline-premium-cj-ft-100?sku=CJ-FT-125&gad_source=1&gad_campaignid=18598503756Takk til vår samarbeidspartner:Oslo skinlab: Osloskinlab.no: rabattkode: bio60 @osloskinlabBoken vår BIOHACKING, - 21 uker på BESTSELGERLISTEN den finner du her:https://www.ark.no/produkt/boker/hobbyboker-og-fritid/biohacking-9788205611474Nysgjerrig på neste Biohacking Weekend 21 og 22 mars 2026? Mail: christin@kongresspartner.no
Tips for ACLS providers to consider when evaluating hypoxia as a possible cause of cardiac arrest and what we can do to correct it.Determining hypoxia using a pulse oximeter or arterial blood gasses (ABGs).A goal of ACLS is to recognize signs of hypoxia and provide timely treatment to prevent an arrest.Examples of some things that might lead us to think of hypoxia as a cause of cardiac arrest.Why pulse ox doesn't give accurate readings during CPR.Delivering ventilations with near 100% oxygen concentration using a BVM attached to supplemental O2 and a reservoir.Using end tidal waveform capnography to assess the quality of CPR.Changes to ventilation rates, tidal volume, and O2 concentration affects a patient's oxygen, carbon dioxide, and pH. The danger of excessive ventilation of a patient in cardiac arrest.**American Cancer Society (ACS) Fundraiser This is the seventh year that I'm participating in Men Wear Pink to increase breast cancer awareness and raise money for the American Cancer Society's life-saving mission.I hope you'll consider contributing.Every donation makes a difference in the fight against breast cancer! Paul Taylor's ACS Fundraiser Page: http://main.acsevents.org/goto/paultaylorTHANK YOU for your support! Good luck with your ACLS class!Links: Buy Me a Coffee at https://buymeacoffee.com/paultaylor Free Prescription Discount Card - Get your free drug discount card to save money on prescription medications for you and your pets: https://safemeds.vip/savePass ACLS Web Site - Other ACLS-related resources: https://passacls.com@Pass-ACLS-Podcast on LinkedIn
Un acuerdo de paz en Gaza se anuncia, con liberación de rehenes y ayuda humanitaria. La Junta de Andalucía realizará mamografías pendientes antes de diciembre. Los españoles no reducirán el gasto en comida. Se prevén fuertes lluvias en el este de España. Oyentes comparten anécdotas de enfado. CADENA 100 presenta la actuación de Leire Martínez el 18 de octubre y sortea entradas para Lady Gaga en Barcelona. Jimeno y Marlon dan conciertos de CADENA 100 en Zaragoza. Se narra la leyenda del pueblo fantasma Willow Creek en California, donde nadie toca nada desde 1859. Melendi, Eiffel 65 y Shakira suenan en CADENA 100. Se mencionan productos y servicios como O2, Fagor, Mutua, Leroy Merlin, Oro Bailén, Mueve, BBVA, Jeep, Movistar Prosegur Alarmas, Mapfre, Don Simón, Legálitas, Lidl Motor V-10, Bruxicalm y Eurodreams.
This week, Sam and Pete check in on GBU's wobbly performance: from losses to one draw, have they taken their eye off the ball??Meanwhile, Sam's picked up a rather questionable new hobby - sending piles of poo to people... and Pete's just received a special delivery in the post. Coincidence? We think not.There's office parking drama, strongly worded reviews, and Sam's big leap into the literary world with his audiobook debut (Sunday Times Best Seller incoming?). Plus, Q.Q.Q.Question Time returns and we dive deep into Sam's unhealthy HP sauce obsession, Pete's secret love for Disney, and the shocking revelation that Sam might actually be able to pull.And in the biggest cliffhanger of all - will Sam actually run a Monday meeting?—
El Gobierno español plantea un registro de médicos objetores de conciencia al aborto. Se informa sobre la repatriación de activistas españoles de Israel y se anuncia el Premio Nobel de Física. La semana de los Premios Nobel está en marcha. Se debate sobre "líneas rojas absurdas" que la gente establece para elegir pareja, como los calcetines con sandalias o la foto de perfil. También se mencionan los cruceros temáticos de juegos de mesa y los "momentos O2" de autocuidado. La música de Bruno Mars con Rosé, Niel Moliner, David Otero y Taburete, Alex Warren, Sebastián Yatra, La Oreja de Van Gogh y Gala ameniza la jornada. Se narra la emotiva historia de un nieto que se reencuentra con su abuela. Unos niños comentan qué deportes no entienden. Vanesa Martín presenta 'Objetos perdidos'. CADENA 100 destaca las ventajas de los seguros Línea Directa, Mapfre y O2, y las ofertas de Euromaster, Viajes El Corte Inglés, Valor, Repsol, Aldi, Opel, Skoda, Teddy, Bruxicalm, Carglass, Halcón Viajes, ...
BE WARNED: It's LuAnna, and this podcast contains honest, upfront opinions, rants, bants and general explicit content. But you know you love it.On this week's LuAnna: The Podcast: Move over Imo - Bex has taken over and looking like 'Marty McFly' in the corner. Anna got squash porned in the thai massage parlour and Lu has been caravaning in Skegness when she could have been on stage at the O2 or at the Four Seasons.Plus, a story about getting frisky in the woods has Anna and Lu in stitches.Remember, if you want to get in touch you can: Email us at luanna@everythingluanna.com OR drop us a WhatsApp on 07745 266947 Please review Global's Privacy Policy: https://global.com/legal/privacy-policy/
This week Sam has clearly had a meeting with a spray tan as he is looking suspiciously orange. Pete isn't letting it slide…it's giving Oompa Loompa. Meanwhile poor Pete is ill, but still soldiers on we pit Pete and Sam against each other as traitor versus faithful. The boys also question if they would survive Race Across the World, and Pete's 66 to 1 odds of becoming the next James Bond spark a debate full of dodgy accents, dreams and unlikely 007s. Elsewhere Pete's series ‘For Dog's Sake' is about to drop with another award nomination in the bag. Sam shares his Halloween plans, relives the moment he got pied off by a Gallagher brother, and admits Louise heard a little too much of his bathroom soundtrack.—
This week the boys tackle how old is too old when it comes to dating? And could Pete and Sam really land themselves sugar mummies… or would it all come down to how much someone would pay to get with Sam?Sam also has a go at sexting, which goes about as well as you'd expect. We also get sent, in Pete's own words, “his favourite email so far,” which, surprisingly, is Great Barr United themed. Plus, the boys plot how they'd fake their own deaths if it ever came to it and what would Sam actually do if Pete went missing? Oh, and when are we finally getting some Staying Relevant merch?—
What If Inclusion, Not Normalization, Was the Goal?Too often, conversations about autism happen without autistic voices at the table. In this episode, we talk with Ari Ne'eman, Assistant Professor at Harvard and co-founder of the Autistic Self-Advocacy Network, about the real divides in autism advocacy and what a better path forward could look like.Ari brings both lived experience and policy expertise, with service under multiple U.S. administrations, to examine how public policy shapes autism services, support, and the future of neurodiversity.This conversation challenges common assumptions and points toward values-driven autism advocacy—centered on communication, inclusion, and real quality of life.Text me your feedback and leave your contact info if you'd like a reply (this is a one-way text). Thanks, DavidSupport the showShow Notes:https://outrageoverload.net/ Follow me, David Beckemeyer, on Twitter @mrblog or email outrageoverload@gmail.com. Follow the show on Twitter @OutrageOverload or Instagram @OutrageOverload. We are also on Facebook /OutrageOverload.HOTLINE: 925-552-7885Got a Question, comment or just thoughts you'd like to share? Call the O2 hotline and leave a message and you could be featured in an upcoming episodeIf you would like to help the show, you can contribute here. Tell everyone you know about the show. That's the best way to support it.Rate and Review the show on Podchaser: https://www.podchaser.com/OutrageOverload Intro music and outro music by Michael Ramir C.Many thanks to my co-editor and co-director, Austin Chen.
This week James Allen delves into a topic that has always fascinated him - the way F1 teams and drivers present themselves – in other words their identity. The F1 season launch at the O2, London in February showed which teams had figured out their identity and those who hadn't. F1 teams go to endless lengths to refine the tiniest details on their car to gain performance, but could they be doing much more to make the cars and drivers look good to fans and sponsors? Is an F1 car livery just a blank canvas to showcase a team's sponsors, or should it say much more than that about the team? How teams show up and what they stand for is really important. Think of the change McLaren went through when Zak Brown took over and switched to papaya orange or when Mercedes switched from Silver Arrows to black cars. We explore this in the company of celebrated designer Nick Downes, who has been creating F1 car liveries and logos for over 30 years, including the iconic yellow “snake” livery for Jordan in the late 1990s, the Jaguars in the early 2000s and more recently for Williams. Send your comments or questions to: @jamesallenonf1 on X or jamesallenonf1@autosport.com. A Motorsport Studios production for Autosport
Fresh off the back of the O2 (and yes, we actually pulled it off), we're debriefing all the highs and lows. From Sam hiding in fear to screens breaking and zero run-throughs, it was pure chaos… but somehow we smashed it and even picked up a seventh world record along the way. We also can't not talk about Pete and Jowita's big dance ending. A massive thank you to everyone who came, supported, and to all our brilliant guests for making it such a night to remember.And moving on from the O2, it's straight into the Staying Relevant book. Pete reveals some exciting potential plans, and there may even be a chance to meet us in real life soon, so keep your eyes peeled.MAFS UK is back, which sparks the question of what Pete and Sam would actually want in a future wife. And after Molly-Mae revealed that baby Bambi has started saying she wants to bite people, we put our own parenting skills to the test by imagining how we'd handle Olive and Rose if they suddenly wanted to bite other kids.
️ LA RUINA está de gira en http://www.laruinashow.com La Ruina desde Valencia con Ignasi Taltavull (@ignasitf), Tomàs Fuentes (@cap0) y Arturo González-Campos matando a Miliki. El juego, la taza y todo el merchandising oficial de La Ruina en https://lallamastore.com/ Este episodio cuenta con la colaboración de O2, la compañía de fibra y móvil. +info en https://o2online.es Ignasi Taltavull: http://www.instagram.com/ignasitf Tomàs Fuentes http://www.twitter.com/cap0 http://www.instagram.com/cap0 La Ruina sigue en redes: @laruinashow http://www.instagram.com/laruinashow
This week, the boys receive an unexpected delivery… a box of sex toys. But the real question is: will Pete actually dare to test out a sex swing?From there, the conversation spirals into a big debate: If Staying Relevant wasn't the name, what would it be? In the process, we uncover Sam and Pete's “hear me outs,” and yes, Mary Berry maybe is Pete's secret crush. And of course, Strictly fever is in full swing. Who's going to take the crown this year? The boys share their predictions and throw their support behind Vicky Pattison and Jowita.
El INE publica los datos de ocupación hotelera y se debate el reconocimiento de Palestina. Aitana Bonmatí gana el Balón de Oro por tercer año consecutivo y Dembélé el masculino. Donald Trump relaciona el paracetamol y el autismo, una afirmación rechazada por la comunidad científica. Un frente de lluvias afecta a Cataluña y Baleares. Los niños comparten sus días más felices, mientras Jimena recuerda su vergüenza al bailar delante de su madre. Una oyente se confunde con la palabra "ovarios" al pedir cita médica, y otra sufre agujetas tras el gimnasio. Se comenta un vídeo viral de una niña que "levita" en la pared. Leire Martínez actuará en CADENA 100. La música de Pink, Backstreet Boys, Fangoria, David Otero y Taburete, Vanessa Martín y Alex Warren anima la jornada. Se anuncian ofertas de O2, El Corte Inglés, Randstad, Iberdrola, Movistar Prosegur Alarmas, CarGlass, Línea Directa, Legalitas, Aena, BBVA, Fiat, Leroy Merlin, Seat y Disneyland París. Se estrena 'Cenicienta el musical' en ...
#406 Rolf Harris' Creepy Toes - Richard is back for a 25th series, but unfortunately pretty much nothing has happened in the news so there's nothing for him to talk about. His guest last appeared on the show almost exactly a decade ago, it's the comedy genius Reece Shearsmith.They chat about his excellent new film “See How They Run” https://www.searchlightpictures.com/see-how-they-run/ and working with the starry cast, why he's not really open to public suggestions for Inside Number Nine locations, the League of Gentleman's journey from the Canal Cafe to the stage at the O2, owning a piece of the Wicker Man and meeting the man from inside the Wicker Man and how Bernie Clifton responded to “Bernie Clifton's Dressing Room”. Plus some magic tricks that probably won't work in the audio podcast, though you can watch the video if you join Acast Plus https://plus.acast.com/s/rhlstp or pay for the video http://gfsboxoffice.comAn absolutely electric show in a packed Leicester Square Theatre - the audience makes this show, so do check out the upcoming bills and come along if you can http://richardherring.com/rhlstpSUPPORT THE SHOW!Watch our TWITCH CHANNELBecome a badger and see extra content at our WEBSITE See details of the RHLSTP TOUR DATES Buy DVDs and books from GO FASTER STRIPE Hosted on Acast. See acast.com/privacy for more information.
Big-time boxing returns to the O2 in October. Former world champion Barry Jones joins Buncey to look ahead to the heavyweight clash between Joseph Parker and Fabio Wardley, with the winner in line to face undisputed world champion Oleksandr Usyk. But who is taking the bigger gamble? We hear from both fighters and promoter Frank Warren.
In the 1960s, continuous electronic fetal monitoring was introduced as a way to better capture and document the fetal response to labor and uterine contraction pattern. Since then, it has become a fully integrated component of intrapartum care despite its limited ability to prevent neonatal long term neurological complications and fetal death. We have covered intrapartum fetal heart rate patterns several times on this show, and this episode now VALIDATES those prior episodes. In this episode, we will summarize THREE key points from the October 2025 upcoming ACOG CPG #10 on “Intrapartum Fetal Heart Rate Monitoring: Interpretation and Management”. Is there a place for intermittent fetal auscultation intrapartum? What about maternal O2 for fetal resuscitation? Are we ready for “AI fetal heart racing interpretations”? Listen in for details.1. ACOG CPG 10: Intrapartum Fetal Heart Rate Monitoring: Interpretation and Management (Oct 2025)2. ACOG PB 205: Vaginal Birth After Cesarean DeliverySTRONG COFFEE PROMO: 20% Off Strong Coffee Company https://strongcoffeecompany.com/discount/CHAPANOSPINOBG
We'd just come off the back of the O2 (well… technically, we recorded this before it happened), so by the time you're listening it either went down as the best night ever or completely t*ts up.Sam's mullet is the talk of the town, but the big question is whether he's finally ready to say goodbye to it. Meanwhile, Pete admits he once rocked a full-on skinhead. With autumn rolling in, we're chatting UGGs, pumpkin spice lattes and Sam's highly questionable Halloween outfit.Since it's the start of uni season, we imagine what kind of students we'd have been if we'd actually gone and whether we'd have even been friends. To top it off, Pete roleplays meeting a uni girlfriend's parents, which leads to a few stories from past encounters with girlfriends' families.
Casi 8 de cada 10 madres en España se sienten mentalmente sobrecargadas, 10 puntos por encima de la media europea. El gobierno planea hacer obligatorias 23 horas semanales lectivas en aula para profesores de primaria y 18 para los de secundaria. Un gran cartel de 'Buenos días, Javi y Mar' luce en Madrid. O2 mejora sus tarifas, priorizando a sus clientes con 5G Plus. La película 'Cinemaría y Sorda' representa a España en los Oscar. Los niños del colegio Valdeluz en 'Buenos días, Javi y Mar' debaten si a sus padres les sobra el dinero. CADENA 100 cubre la Madrid Fashion Week. Se escucha música de Avicii, Dua Lipa con 'Hudini' y Ricky Martin con 'Livin' la vida loca'. Los oyentes comparten anécdotas de situaciones incómodas en baños del trabajo y discuten la vida laboral.
Más de cincuenta años después de que Nixon la declarara, la guerra contra las drogas vive una nueva escalada con Trump. La designación de cárteles mexicanos como organizaciones terroristas y la autorización de ataques militares fuera del territorio estadounidense marcan un punto de inflexión en esta estrategia que ha fracasado sistemáticamente. Desde la Ley Seca hasta el fentanilo, analizamos cómo la mano dura perpetúa la violencia mientras ignora las causas de fondo. Hoy en "No es el fin del mundo" hablamos de la guerra contra las drogas en Estados Unidos. No tenemos los enlaces para inscribirse en los directos de Canarias y San Sebastián todavía, ¡lo anunciaremos en cuanto podamos! Este episodio cuenta con una mención publicitaria de O2.
RHLSTP #580 - Pea on the Cob - As if there weren't enough people here for the Festival, Edinburgh numbers are swollen by Oasis fans, though Rich adlibs a decent joke for once, so it's worth listening to the intro. His guest is RHLSTP favourite, Tim Key. They chat about being locked out of flats, broken cat-flaps, the year of the Herring and how much O2 paid to sponsor RHLSTP (in the golden era), Tim's appearance in the new Greg Daniels sitcom The Paper and Robert Popper's part in getting him there, 5k times and the pathetic money-making crimes that Richard never got caught for in 1989 (if you were one of the students he took to HMS Victory please get in touch for your rebate). Plus selling Dawn French a yoyo and nearly killing Michael Palin. It's another classic Key:Herring collaboration, awkward, weird, boring and funny enough to almost make Richard pass out.Buy Tim's fantastic LA Baby here https://uk.bookshop.org/p/books/l-a-baby-tim-key/7870201See RHLSTP live http://richardherring.com/rhlstpSUPPORT THE SHOW!Watch our TWITCH CHANNELBecome a badger and see extra content at our WEBSITE See details of the RHLSTP TOUR DATES Buy DVDs and books from GO FASTER STRIPE Hosted on Acast. See acast.com/privacy for more information.
Why Owning Your Online Identity Matters More Than EverIs it possible to fix social media? In this episode, I'm joined by Yevgeny Simkin, Co-Founder of Sez.us, a new social media platform built to encourage civility and healthier online spaces.We talk about why we need real alternatives to Facebook and Twitter, who controls online conversations today, and how owning your online identity could change the way communities connect. Yevgeny explains why escaping social media giants might be the first step toward better ways to connect online and how community-driven platforms can reshape our digital future.If you've ever wondered whether social media could be less toxic and more human, this conversation offers both hope and a roadmap.Listen now to explore how Sez.us is rethinking what social media can be.Text me your feedback and leave your contact info if you'd like a reply (this is a one-way text). Thanks, DavidSupport the showShow Notes:https://outrageoverload.net/ Follow me, David Beckemeyer, on Twitter @mrblog or email outrageoverload@gmail.com. Follow the show on Twitter @OutrageOverload or Instagram @OutrageOverload. We are also on Facebook /OutrageOverload.HOTLINE: 925-552-7885Got a Question, comment or just thoughts you'd like to share? Call the O2 hotline and leave a message and you could be featured in an upcoming episodeIf you would like to help the show, you can contribute here. Tell everyone you know about the show. That's the best way to support it.Rate and Review the show on Podchaser: https://www.podchaser.com/OutrageOverload Intro music and outro music by Michael Ramir C.Many thanks to my co-editor and co-director, Austin Chen.
Se debate sobre la Vivienda de Protección Oficial y los límites de precios. Los sindicatos policiales denuncian la gestión del gobierno en una operación, con quejas por falta de órdenes claras y riesgo para ciclistas y policías. La Unión Ciclista Internacional duda de la capacidad de España para albergar grandes eventos. Ed Sheeran felicita las fiestas patronales de La Algaida, Murcia, revelando un vínculo familiar. En 'Buenos días, Javi y Mar', los oyentes comparten experiencias: Cristina duerme en el coche frente a un cementerio en una competición de Scalextric; Tomás dura 2 minutos en un retiro de silencio al reírse; Karina acompaña a su novio al baño porque tiene miedo. Se habla de hábitos al hacer la cama y de O2 como una decisión acertada. Jimeno y los niños imaginan qué harían siendo los más ricos del mundo. Se discuten estrategias de pareja como 'la crecida de los orcos' y el 'skreek'. Se menciona una canción inspirada en Rebeca Méndez Jiménez, que espera a su amor en el ...
Se informa sobre la actualidad, incluyendo un incendio, la entrada de drones rusos en espacio aéreo polaco, la conmemoración del 11 de septiembre y la celebración de la Diada en Cataluña. En 'Buenos días, Javi y Mar' anuncian el creador del himno de CADENA 100 y hablan sobre experiencias en la oscuridad, con anécdotas de golpes y sustos. También debaten sobre lo primero que se mira al llegar a un hotel, destacando la limpieza y el baño. Se realizan sorteos de dinero. Se escucha música de Marlon y Álvaro de Luna, 'My Own Peculiar Way' y Liam Raymes. Varias empresas como O2, Fiat, Nissan y Mutua Madrileña tienen promociones. Se abordan reflexiones sobre la salud mental y la familia. Se promocionan Movistar Prosegur Alarmas, Banco Sabadell, BBVA y Calvo. Se presenta la canción 'Roar' de Katy Perry. Se anuncia la venta de entradas para el CADENA 100 por ellas el 19 de septiembre y se comenta que Leire de La Oreja de Van Gogh vende objetos personales en Wallapop. El programa cierra con el ...
Gen Z's political gender gap is widening. Young women are trending left, while young men drift right—and it's not just politics. In this episode, we explore the cultural, social, and economic pressures shaping young men's identities, from the “manosphere” to societal expectations around masculinity and the pressure to be the breadwinner.We examine the consequences for democracy, social cohesion, and the future of civic engagement—and consider how society can create better spaces for young men to belong, participate, and thrive.What you'll learn in this episode:Why young men are drawn to exclusionary spaces onlineHow societal pressures around masculinity and economic roles influence political choicesThe role of both the left and right in widening the gender gapWhy this divide matters for democracy and social stabilityPaths toward healthier engagement and belongingGuests:Rev. Angela Denker, award-winning author and journalistMark Sutton, gender expert and author of How Democrats Can Win Back MenEric Kaufmann, Professor of Politics and author of The Third AwokeningText me your feedback and leave your contact info if you'd like a reply (this is a one-way text). Thanks, DavidFor the Young men turning red episode Support the showShow Notes:https://outrageoverload.net/ Follow me, David Beckemeyer, on Twitter @mrblog or email outrageoverload@gmail.com. Follow the show on Twitter @OutrageOverload or Instagram @OutrageOverload. We are also on Facebook /OutrageOverload.HOTLINE: 925-552-7885Got a Question, comment or just thoughts you'd like to share? Call the O2 hotline and leave a message and you could be featured in an upcoming episodeIf you would like to help the show, you can contribute here. Tell everyone you know about the show. That's the best way to support it.Rate and Review the show on Podchaser: https://www.podchaser.com/OutrageOverload Intro music and outro music by Michael Ramir C.Many thanks to my co-editor and co-director, Austin Chen.
Alertas por tormentas en Baleares, Cataluña y Comunidad Valenciana; clases suspendidas en Alicante. España e Israel intercambian prohibiciones de entrada a políticos por el conflicto en Gaza. Se convalidan nuevos permisos de paternidad/maternidad: 17 semanas retribuidas más 2 de cuidados hasta los 8 años. El regreso a las aulas se ha visto afectado por huelgas de profesores en varias comunidades, mientras otras lo hacen con normalidad. Se mencionan anécdotas personales y ofertas de O2.
JoJo Siwa who has truly done it all since she rose to fame at just 11 years old in the reality TV show, Dance Moms. Since then JoJo has gone on to sell over 90 million hair bows as part of a billion dollar empire, had her own Nickelodeon show, launched a hugely successful YouTube channel, notch up billions of views and music streams and became the youngest person to sell out the O2 arena. As JoJo prepares to go back on tour in October with new music she joins to have a very honest chat about her identity and her sexuality after she came out in 17 and recently formed a romantic relationship with Chris Hughes on Celebrity Big Brother UK. This chat is filled with honesty and I hope this shows you that no matter how you identify that no one has the right to your identity and you should live your life for you and on your terms. If you enjoy listening to JoJo's story, get in touch as I always love chatting to you and you can find me @joshsmithhosts across socials. Love, Josh x TO BE CONFIRMED P.S. I'm really excited to be working with Primark - our go to for smart shopping and off the moment trends. Primark are serving us the best new denim collection for autumn with every fit imaginable: wide leg, palazzo, barrel, bootleg, or baggy. Primark's denim has a look for literally every occasion and for everyone because like Reign, Primark wants to empower you to celebrate you and your style everyday, no matter the occassion. Head to primark.com to browse the collection, and why not try the click and collect service while you're there babes?! P.P.S If this great chat has left you wanting to improve your communication skills and boost your relationships - and build new ones- in the process check out my self help book, ‘Great Chat: Talk to Anyone. Build New Connections. Improve Your Relationships' which is out now in paperback. Whether you are socially anxious, struggling to make connections on dates or want to learn how to have difficult conversations, this is the book for you! You can get your copy here https://geni.us/GreatChat and I really hope you love it. Include the p.s from Primark Learn more about your ad choices. Visit podcastchoices.com/adchoices
Our primary focus immediately following return of spontaneous circulation (ROSC) is aimed at ensuring adequate perfusion of the patient's vital organs and decreasing cerebral damage.Post-arrest goals for O2 saturation, ETCO2, and BP/MAP.Indications for use of an antiarrhythmic after ROSC.Determining which antiarrhythmic to use post cardiac arrest.Administration of Amiodarone or Lidocaine to control ventricular ectopy after ROSC.The use of Amiodarone post arrest if no antiarrhythmics were administered prior to obtaining ROSC.Links to other medical podcasts that cover antiarrhythmics and other ACLS-related topics are on the Pod Resource page at PassACLS.com.**American Cancer Society (ACS) Fundraiser This is the seventh year that I'm participating in Men Wear Pink to increase breast cancer awareness and raise money for the American Cancer Society's life-saving mission.I hope you'll consider contributing.Every donation makes a difference in the fight against breast cancer! Paul Taylor's ACS Fundraiser Page: http://main.acsevents.org/goto/paultaylorTHANK YOU for your support! Good luck with your ACLS class!Links: Buy Me a Coffee at https://buymeacoffee.com/paultaylor Free Prescription Discount Card - Get your free drug discount card to save money on prescription medications for you and your pets: https://safemeds.vip/savePass ACLS Web Site - Other ACLS-related resources: https://passacls.com@Pass-ACLS-Podcast on LinkedIn
It was an interesting weekend all the way around with fight cards in Ireland and two in Mexico and we have those recaps, plus, there's plenty of fight news, including two legends that are apparently going to fight despite being some 80 lbs apart?! Yes, indeed and we'll cover it on the "Fight Freaks Unite Recap Podcast."Host T.J. Rives is back with insider Dan Rafael of his Fight Freaks Unite Substack and Newsletter to cover it all with their thoughts.First, they recap the Matchroom main event Saturday on DAZN in Los Mochis, MexicoJunior lightweight Eduardo “Sugar” Nunez decisions Christopher Diaz and retains his IBF title. TREMENDOUS FIGHT says Dan. They have more. Next, the Recap of the Zanfer Promotions main event Saturday on ESPN Deportes in Nogales, MexicJunior lightweight and former two division world champ Oscar Valdez decisions Ricky Medina, and rebounds from his KO loss to Navarrete in their title rematch. Plus, a quick recap of the Wasserman Boxing main event on Friday in Dublin, IrelandFeatherweight former title challenger Michael Conlan scores an easy TOK4 of Jack Bateson.Then, some NewsFloyd Mayweather and Mike Tyson sign for spring exhibition!! WHAT ARE WE DOING HERE!?!Queensberry formally announces Joseph Parker vs. Fabio Wardley heavyweight fight for Oct. 25 at The O2 in London on DAZN PPV. Presser on Tuesday in London. Winner is Usyk mandatory. And, Frank Warren confirms rising heavyweight star Moses Itauma will be back Dec.13 to headline at Co-op Live in Manchester, England. Opponent TBA.Eddie Hearn confirms Anthony Joshua, who is recovering from elbow surgery, won't fight the rest of this year and will likely return Jan/Feb and there is interest in him fighting in Ghana.This is wild – WBC held a purse bid on Friday for the rematch between cruiserweight titlist Badou Jack and former titlist Noel Mikaelian. Two bids and it was a tie!!! The WBC said that has never happened before. Made them bid again and Bash Promotions won!It's all part of the "Fight Freaks Unite Recap Podcast" and make sure to follow/subscribe on Apple/Spreaker/Spotify, etc.!
Dr. Pedro Barata and Dr. Rana McKay discuss the integration of innovative advances in molecular imaging and therapeutics to personalize treatment for patients with renal cell and urothelial carcinomas. TRANSCRIPT Dr. Pedro Barata: Hello, I'm Dr. Pedro Barata, your guest host of By the Book, a podcast series featuring insightful conversations between authors and editors of the ASCO Educational Book. I'm a medical oncologist at University Hospitals Seidman Cancer Center and an associate professor of medicine at Case Western Reserve University in Cleveland, Ohio. I'm also an associate editor of the ASCO Educational Book. Now, we all know the field of genitourinary cancers (GU) is evolving quite rapidly, and we have new innovations in molecular imaging as well as targeted therapeutics. Today's episode will be exploring novel approaches that are transforming the management of renal cell and urothelial carcinomas and also their potential to offer a more personalized treatment to patients. For that, joining for today's discussion is Dr. Rana McKay, a GU medical oncologist and professor at University of California San Diego. Dr. McKay will discuss her recently published article titled, “Emerging Paradigms in Genitourinary Cancers: Integrating Molecular Imaging, Hypoxia-Inducible Factor-Targeted Therapies, and Antibody-Drug Conjugates in Renal Cell and Urothelial Carcinomas.” Our full disclosures are available in the transcript of this episode. And with that, Rana McKay, great to have you on the podcast today. Dr. Rana McKay: Oh, thank you so much, Dr. Barata. It's really wonderful to be here with you. So, thanks for hosting. Dr. Pedro Barata: No, thanks for taking the time, and I'm looking forward to this conversation. And by the way, let me start by saying congrats on a great article in the Educational Book. Really super helpful paper. I'm recommending it to a lot of the residents and fellows at my own institution. I would like to first ask you to kind of give our listeners some context of how novel approaches in the molecular imaging as well as targeted therapeutics are actually changing the way we're managing patients with GU, but specifically with renal cell carcinoma and urothelial carcinoma. So, what are the areas you would call out as like being big areas for innovation in this context, and why are they important? Dr. Rana McKay: Very good question. And I think this is really what this article highlights. It highlights where are we going from an imaging diagnostics standpoint? Where are we going from a therapeutic standpoint? And I think if we have to step back, from the standpoint of diagnostics, we've seen PET imaging really transform diagnostics in prostate cancer with the advent of PSMA PET imaging, and now PSMA PET imaging is used as a biomarker for selection for theranostics therapy. And so, we're starting to see that enter into the RCC landscape, enter into the urothelial cancer landscape to a lesser extent. And I think it's going to potentially be transformative as these tools get more refined. I think when we think about therapeutics, what's been transformative most recently in the renal cell carcinoma landscape has been the advent of HIF2α inhibition to improve outcomes for patients. And we have seen the approval of belzutifan most recently that has reshaped the landscape. And now there's other HIF2α inhibitors that are being developed that are going to be further important as they get refined. And lastly, I think when we think about urothelial carcinoma, the greatest transformation to treatment in that context has been the displacement of cisplatin and platinum-based chemotherapy as a frontline standard with the combination of enfortumab vedotin plus pembrolizumab. And we've seen antibody-drug conjugates really reshape treatment and tremendously improve outcomes for patients. So, I think those are the three key areas of interest. Dr. Pedro Barata: So with that, let's focus first on the imaging and then we'll get to the therapeutic area. So, we know there's been a paradigm shift, really, when prostate-specific targets emerged as tracers for PET scanning. And so, we now commonly use prostate-specific membrane antigen, or PSMA-based PET scanning, and really transform how we manage prostate cancer. Now, it appears that we're kind of seeing a similar wave in renal cell carcinoma with the new radiotracer against the target carbonic anhydrase IX. What can you tell us about this? And is this going to be available to us anytime soon? And how do you think that might potentially change the way we're managing patients with RCC today? Dr. Rana McKay: First, I'll step back and say that in the context of PSMA PET imaging, we have actually been able to better understand RCC as well. So, we know that PSMA is expressed in the neovasculature of tumors, and it can actually be used to detect renal cell carcinoma tumors. It has a detection rate of about 84% when used for detection. And so, you know, I don't think it's just restricted to carbonic anhydrase IX, but we will talk about that. So, PSMA expressed in the neovasculature has a detection rate of around 84%, particularly if we're looking at clear cell RCC. CAlX is overexpressed in clear cell RCC, and it's actually used in diagnosing renal cell carcinoma when we think of CAlX IHC for diagnosing clear cell RCC. And now there are CAlX PET tracers. The first foray was with the ZIRCON study that was actually an interestingly designed study because it was designed to detect the likelihood of PET imaging to identify clear cell RCC. So, it was actually used in the early diagnostics setting when somebody presents with a renal mass to discriminate that renal mass from a clear cell versus a non-clear cell, and it was a positive study. But when I think about the potential application for these agents, you know, I think about the entire landscape of renal cell carcinoma. This is a disease that we do treat with metastasis-directed therapy. We have certainly seen patients who've undergone metastasectomy have long, durable remissions from such an approach. And I think if we can detect very early onset oligometastatic disease where a metastasis-directed therapy or SABR could be introduced - obviously tested in a trial to demonstrate its efficacy - I think it could potentially be transformative. Dr. Pedro Barata: Wonderful. It's a great summary, and I should highlight you are involved in some of those ongoing studies testing the performance of this specific PET scanning for RCC against conventional imaging, right? And to remind the listeners, thus far, for the most part, we don't really do FDG-PET for RCC. There are some specific cases we do, but in general, they're not a standard scanning. But maybe that will change in the future. Maybe RCC will have their own PSMA-PET. And to your point, there's also emerging data about the role of PSMA-PET scanning in RCC as well, as you very elegantly summarized. Wonderful. So, let me shift gears a little bit because you did, in your introduction, you did highlight a novel MOA that we have in renal cell carcinoma, approved for use, initially for VHL disease, and after that for sporadic clear cell renal cell carcinoma. We're talking about hypoxia-inducible factor 2-alpha inhibitors, or HIF2α inhibitors, such as belzutifan. But there's also others coming up. So, as a way to kind of summarize that, what can you tell us about this breakthrough in terms of therapeutic class, this MOA that got to our toolbox of options for patients with advanced RCC? Tell us a little bit what is being utilized currently in the management of advanced RCC. And where do you see the future going, as far as, is it moving early on? Is it getting monotherapy versus combinations? Maybe other therapies? What are your thoughts about that? What can you tell us about it? Dr. Rana McKay: Belzutifan is a first-in-class HIF2α inhibitor that really established clinical validation for HIF2α as a therapeutic target. When we think about the activity of this agent, the pivotal LITESPARK-005 trial really led to the approval of belzutifan in patients who were really heavily pretreated. It was patients who had received prior IO therapy, patients who had received prior VEGF-targeted therapy. And in the context of this study, we saw a median PFS of 5.6 months, and there did seem to be a tail on the curve when you looked at the 12-month PFS rate with belzutifan. It was 33.7% compared to 17.6% with everolimus. And then when we look at the response rate, it was higher with belzutifan on the order of 22-23%, and very low with everolimus, as we've previously seen. I think one of the Achilles heels of this regimen is the primary PD rate, which was 34% when used in later line. There are multiple studies that are testing belzutifan in combination across the treatment landscape. So, we have LITESPARK-011, which is looking at the combination of belzutifan plus lenvatinib in the second-line setting. We've got the MK-012 [LITESPARK-012] study, which is looking at belzutifan in various combinations in the frontline setting. So there is a combination with IO plus belzutifan. And so this is also being looked at in that context. And then we also have the LITESPARK-022 study, which is looking at pembrolizumab with belzutifan in the adjuvant setting. So there's a series of studies that will be exploring belzutifan really across the treatment landscape. Many of these studies in combination. Additionally, there are other HIF2α inhibitors that are being developed. We have casdatifan, which is another very potent HIF2α inhibitor. You know, I think pharmacologically, these are different agents. There's a different half-life, different dosing. What is going to be the recommended phase 3 dose for both agents, the EPO suppression levels, the degree of EPO suppression, and sustainability of EPO suppression is very different. So, I think we've seen data from casdatifan from the ARC-20 trial from monotherapy with a respectable response rate, over 30%, primary PD rate hovering just around 10%. And then we've also seen data of the combination of casdatifan with cabozantinib as well that were recently presented this year. And that agent is also being tested across the spectrum of RCC. It's being looked at in combination with cabozantinib in the PEAK-1 study, and actually just at the KCRS (Kidney Cancer Research Summit), we saw the unveiling of the eVOLVE-RCC trial, which is going to be looking at a volrustomig, which is a PD-1/CTLA-4 inhibitor plus casdatifan compared to nivo-ipi in the frontline setting. So, we're going to see some competition in this space of the HIF2α inhibitors. I think when we think of mechanism of action in that these are very potent, not a lot of off-target activity, and they target a driver mutation in the disease. And that driver mutation happens very early in the pathogenesis. These are going to be positioned much earlier in the treatment landscape. Dr. Pedro Barata: All these studies, as you're saying, look really promising. And when we talk about them, you mentioned a lot of combinations. And to me, when I think of these agents, it makes a lot of sense to combine because there's not a lot of overlapping toxicities, if you will. But perhaps for some of our listeners, who have not used HIF2α inhibitors in practice yet, and they might be thinking about that, what can you tell us about the safety profile? How do you present it to your patients, and how do you handle things like hypoxia or anemia? How do you walk through the safety profile and tolerability profile of those agents like belzutifan? Dr. Rana McKay: I think these drugs are very different than your traditional TKIs, and they don't cause the classic symptoms that are associated with traditional TKIs that many of us are very familiar with like the rash, hand-foot syndrome, hypertension, diarrhea. And honestly, these are very nuanced symptoms that patients really struggle with the chronicity of being on a chronic daily TKI. The three key side effects that I warn patients about with HIF2α inhibitors are: (1) fatigue; (2) anemia; and (3) hypoxia and dysregulation in the ability to sense oxygen levels. And so, many of these side effects - actually, all of them - are very dose-dependent. They can be very well-managed. So, we can start off with the anemia. I think it's critically important before you even start somebody on belzutifan that you are optimizing their hemoglobin and bone marrow function. Make sure they don't have an underlying iron deficiency anemia. Make sure they don't have B12 or folate deficiency. Check for these parameters. Many patients who have kidney cancer may have some hematuria, other things where there could be some low-level blood loss. So, make sure that those are resolved or you're at least addressing them and supplementing people appropriately. I monitor anemia very closely every 3 to 4 weeks, at least, when people start on these medications. And I do initiate EPO, erythropoietin, should the anemia start to worsen. And I typically use a threshold of around 10g/dL for implementing utilization of an EPO agent, and that's been done very safely in the context of the early studies and phase 3 studies as well. Now, with regards to the hypoxia, I think it's also important to make sure that you're selecting the appropriate individual for this treatment. People who have underlying COPD, or even those individuals who have just a very high burden of disease in their lung, lymphangitic spread, pleural effusions, maybe they're already on oxygen - that's not an ideal candidate for belzutifan. Something that very easily can be done in the clinic before you think about initiating somebody on this treatment, and has certainly been integrated into some of the trials, is just a 6-minute walk test. You know, have the patient walk around the clinic with one of the MAs, one of the nurses, put the O2 sat on [measuring oxygen saturation], make sure they're doing okay. But these side effects, like I said, are very dose-dependent. Typically, if a patient requires, if the symptoms are severe, the therapy can be discontinued and dose reduced. The standing dose is 120 mg daily, and there's two dose reductions to 80 mg and 40 mg should somebody warrant that dose modification. Dr. Pedro Barata: This is relatively new, right? Like, it was not that we're used to checking oxygen levels, right? In general, we're treating these patients, so I certainly think there's a learning curve there, and some of the points that you highlight are truly critical. And I do share many of those as well in our practice. Since I have you, I want to make sure we touch base on antibody-drug conjugates as well. It's also been a hot area, a lot of developments there. When I think of urothelial carcinoma and renal cell carcinoma, I see it a little bit different. I think perhaps in urothelial carcinoma, antibody-drug conjugates, or ADCs, are somewhat established already. You already mentioned enfortumab vedotin. I might ask you to expand a little bit on that. And then in renal cell carcinoma, we have some ADCs as well that you include in your chapter, and that I would like you to tell us what's coming from that perspective. So, tell us a little bit about how do you see ADCs in general for GU tumors, particularly UC and RCC? Tell us a little bit about the complexity or perhaps the challenges you still see. At the same time, tell us about the successes. Dr. Rana McKay: Stepping back, let's just talk about like the principles and design of ADCs. So, most ADCs have three components. There's a monoclonal antibody that typically targets a cell surface antigen, which is conjugated by a linker, which is the second component, to a payload drug. And typically, that payload drug has been chemotherapy, whether it be topoisomerase or whether it be MMAE or other chemotherapeutic. We can start in the RCC space. There's been multiple antibody-drug conjugates that have been tested. There's antibody-drug conjugates to CD70, which is expressed on clear cell RCC. There's been antibody-drug conjugates to ENPP3, which is also expressed on RCC. There's antibody-drug conjugates to CDH6. And they have different payloads, like I said, whether it be topoisomerase I or other microtubule inhibitors. Now, when we think about kidney cancer, we don't treat this disease with chemotherapy. This disease is treated with immunotherapy. It is treated with treatments that target the VEGF pathway and historically has not been sensitive to chemo. So, I think even though the targets have been very exciting, we've seen very underwhelming data regarding activity, and in some context, seen increased toxicity with the ADCs. So, I think we need to tread lightly in the context of the integration and the testing of ADCs in RCC. We just came back from the KCRS meeting, and there was some very intriguing data about a c-Kit ADC that's being developed for chromophobe RCC, which is, you know, a huge unmet need, these variant tumors that really lack appropriate therapeutics. But I just caution us to tread lightly around how can we optimize the payload to make sure that the tumor that we're treating is actually sensitive to the agent that's targeting the cell kill. So, that's a little bit on the ADCs in RCC. I still think we have a long way to go and still in early testing. Now, ADCs for UC are now the standard of care. I think the prototypical agent, enfortumab vedotin, is a nectin-4-directed ADC that's conjugated to an MMAE payload and was the first ADC approved for advanced urothelial, received accelerated approval following the EV-201 trial, which was basically a multicenter, single-arm study that was investigating EV in cisplatin-ineligible patients with advanced urothelial carcinoma, and then ultimately confirmed in the EV-301 study as well. And so, that study ended up demonstrating the support superiority of EV from an overall survival standpoint, even PFS standpoint. Building on that backbone is the EV-302 study, which tested EV in combination with pembrolizumab versus platinum-based chemotherapy in the frontline setting. And that was a pivotal, landmark study that, like I said, has displaced platinum therapy as a frontline treatment for people with advanced urothelial carcinoma. And when we think about that study and the median overall survival and just how far we've come in urothelial cancer, the median OS with EV-pembro from that trial was 31 and a half months. I mean, that's just incredible. The control arm survival was 16 and a half months. The hazard ratio for OS, 0.47. I mean this is why when this data was presented, it was literally a standing ovation that lasted for several minutes because we just haven't seen data that have looked that good. And there are other antibody-drug conjugates that are being tested. We've all been involved in the saga with sacituzumab govitecan, which is a trophoblast cell surface antigen 2 (Trop-2) targeted ADC with a topoisomerase I payload. It was the second ADC to receive approval, but then that approval was subsequently withdrawn when the confirmatory phase 3 was negative, the TROPiCS-04 trial. So, approval was granted based off of the TROPHY-U-01, single-arm, phase 2 study, demonstrating a response rate of around 28% and a PFS of, you know, about 5 and a half months. But then failure to show any benefit from an OS standpoint. And I think there's a lot of controversy in the field around whether this agent still has a role in advanced urothelial carcinoma. And I think particularly for individuals who do not have molecular targets, like they're not HER2-amplified or have HER2-positivity or FGFR or other things like that. Dr. Pedro Barata: Fantastic summary, Rana. You were talking about the EV, and it came to mind that it might not be over, right, for the number of ADCs we use in clinical practice in the near future. I mean, we've seen very promising data for ADC against the HER2, right, and over-expression. It also can create some challenges, right, in the clinics because we're asking to test for HER2 expression. It's almost like, it's not exactly the same to do it in breast cancer, but it looks one more time that we're a little bit behind the breast cancer field in a lot of angles. And also has vedotin as a payload. Of course, I'm referring to disitamab vedotin, and there's very elegant data described by you in your review chapter as well. And it's going to be very interesting to see how we sequence the different ADCs, to your point as well. So, before we wrap it up, I just want to give you the opportunity to tell us if there's any area that we have not touched, any take-home points you'd like to bring up for our listeners before we call it a day. Dr. Rana McKay: Thank you so much. I have to say, you know, I was so excited at ASCO this year looking at the GU program. It was fantastic to see the progress being made, novel therapeutics that really there's a tremendous excitement about, not just in RCC and in UC, but also in prostate cancer, thinking about the integration of therapies, not just for people with refractory disease that, even though our goal is to improve survival, our likelihood of cure is low, but also thinking about how do we integrate these therapies early in the treatment landscape to enhance cure rates for patients, which is just really spectacular. We're seeing many of these agents move into the perioperative setting or in combination with radiation for localized disease. And then the special symposium on biomarkers, I mean, we've really come a long, long way. And I think that we're going to continue to evolve over the next several years. I'm super excited about where the field is going in the treatment of genitourinary malignancies. Dr. Pedro Barata: Oh, absolutely true. And I would say within the Annual Meeting, we have outstanding Educational Sessions. And just a reminder to the listeners that actually that's where the different teams or topics for the Educational Book chapters come from, from actually the educational sessions from ASCO. And your fantastic chapter is an example of that, right, focusing on advanced GU tumors. So, thank you so much, Rana, for taking the time, sharing your insights with us today on the podcast. It was a fantastic conversation as always. Dr. Rana McKay: My pleasure. Thanks so much for having me, Dr. Barata. Dr. Pedro Barata: Of course. And thank you to our listeners for your time today. You will find the link to the article discussed today in the transcript of this episode. I also encourage you to check out the 2025 ASCO Educational Book. You'll find an incredible wealth of information there. It's free, available online, and you'll find, hopefully, super, super important information on the key science and issues that are shaping modern oncology, as we've heard from Dr. McKay and many other outstanding authors. So, thank you, everyone, and I hope to see you soon. Disclaimer: The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement. Follow today's speakers: Dr. Pedro Barata @PBarataMD Dr. Rana McKay @DrRanaMcKay Follow ASCO on social media: @ASCO on X (formerly Twitter) ASCO on Bluesky ASCO on Facebook ASCO on LinkedIn Disclosures: Dr. Pedro Barata: Stock and Other Ownership Interests: Luminate Medical Honoraria: UroToday Consulting or Advisory Role: Bayer, BMS, Pfizer, EMD Serono, Eisai, Caris Life Sciences, AstraZeneca, Exelixis, AVEO, Merck, Ipson, Astellas Medivation, Novartis, Dendreon Speakers' Bureau: AstraZeneca, Merck, Caris Life Sciences, Bayer, Pfizer/Astellas Research Funding (Inst.): Exelixis, Blue Earth, AVEO, Pfizer, Merck Dr. Rana McKay: Consulting or Advisory Role: Janssen, Novartis, Tempus, Pfizer, Astellas Medivation, Dendreon, Bayer, Sanofi, Vividion, Calithera, Caris Life Sciences, Sorrento Therapeutics, AVEO, Seattle Genetics, Telix, Eli Lilly, Blue Earth Diagnostics, Ambrx, Sumitomo Pharma Oncology, Esiai, NeoMorph, Arcus Biosciences, Daiichi Sankyo, Exelixis, Bristol Myers Squibb, Merck, Astrazeneca, Myovant Research Funding (Inst.): Bayer, Tempus, AstraZeneca, Exelixis, Bristol Myers Squibb, Oncternal Therapeutics, Artera
The Shift from Certainty to NuanceWe've all heard the saying: facts don't change minds. But new research challenges that idea.In this episode, David talks with social scientist Nick Stagnaro about what happens when people dive deep into the facts on divisive issues like gun control. The findings? Knowledge can soften extreme positions—shifting people toward a more nuanced middle ground.But here's the catch: while attitudes toward policies change, feelings toward people on the “other side” often don't. That puzzle drives Nick's research into belief change, polarization, and how credibility, trust, and even AI-driven debates might help bridge divides.Listen in to explore how facts can move us—and where they fall short.Text me your feedback and leave your contact info if you'd like a reply (this is a one-way text). Thanks, David9 second versionSupport the showShow Notes:https://outrageoverload.net/ Follow me, David Beckemeyer, on Twitter @mrblog or email outrageoverload@gmail.com. Follow the show on Twitter @OutrageOverload or Instagram @OutrageOverload. We are also on Facebook /OutrageOverload.HOTLINE: 925-552-7885Got a Question, comment or just thoughts you'd like to share? Call the O2 hotline and leave a message and you could be featured in an upcoming episodeIf you would like to help the show, you can contribute here. Tell everyone you know about the show. That's the best way to support it.Rate and Review the show on Podchaser: https://www.podchaser.com/OutrageOverload Intro music and outro music by Michael Ramir C.Many thanks to my co-editor and co-director, Austin Chen.
Welcome to Season Four of Road to the Trials!This will be the most epic season yet as we look to interview every qualifier to the 2028 Olympic Marathon Trials in Los Angeles as well as plenty of industry professionals along the way. Our expanded goal is matched by our expanding team! We now have three co-hosts - Matt Chittim, Lindsey Hein, and Peter Bromka.We are thrilled to be your central hub for everything related to the Olympic Marathon Trials. This season, we're diving deep into the stories, challenges, and triumphs of athletes on their journey to the Trials.Follow us on Instagram @RoadToTheTrials for behind-the-scenes content and post-race highlights as well as our new website www.roadtothetrials.com.SponsorBig shout-out to the best coaching platform in the business - V.O2. V.O2 was built from the foundation of a scientifically-validated training methodology. Based on former Olympian, author, and legendary running coach Jack Daniels' exercise science principles, the methodology not only benefits runners of all ages and abilities when it comes to improving their running fitness but it also serves as the best measure of running economy. Visit https://vdoto2.com today for more information.
The boys are heading off on holiday, but with very different agendas. Sam is in full “Uncle Sam” mode, third wheeling his sister's trip with baby Leo, while Pete insists he's off to Ibiza for work. As part of his Ibiza prep, Pete tries his hand at a practice vibe check call as we put him on the spot to call up Sheesh…Meanwhile, all that nephew time has Sam feeling surprisingly broody, while Pete's focused on the O2. With the NTAs around the corner, the boys look back on last year's red-carpet drama and spill a little behind-the-scenes gossip.
Joining us this episode to discuss the highs and lows of parenting (and life) is the brilliant singer, songwriter and presenter - Olly Murs. Fresh off a sold-out Arena tour, including three massive dates in London (two at The O2 & one at Wembley Arena), Olly Murs is currently back on the road continuing his 15 Years Of Hits celebration across the UK with a run of outdoor summer shows. With seven studio albums under his belt, including five chart topping records, Olly just released his new single 'Save Me' and has an album due later in the year. Tour dates: August 2025 Fri 29th Blackpool, Illuminations Sat 30th Jedburgh, Edge Fest Parenting Hell is a Spotify Podcast, available everywhere every Tuesday and Friday. Please subscribe and leave a rating and review you filthy street dogs... xx If you want to get in touch with the show with any correspondence, kids intro audio clips, small business shout outs, and more.... here's how: EMAIL: Hello@lockdownparenting.co.uk Follow us on instagram: @parentinghell A 'Keep It Light Media' Production Sales, advertising, and general enquiries: hello@keepitlightmedia.com Learn more about your ad choices. Visit podcastchoices.com/adchoices
Dr. Jeff Gross — Board-certified neurological surgeon, biochemist, biohacker, founder of Celebrate Regenerative Medicine, and longevity/biohacking consultant based in Las Vegas & Southern California. Medical & Health Longevity Background: Dr. Gross trained at UC Berkeley (Biochemistry & Molecular Biology), George Washington University School of Medicine, UC Irvine (Neurosurgery), and UNM (Spinal Biomechanics). He has decades of frontline experience in spine surgery, sports injuries, regenerative medicine, and now consults on biohacking and longevity. Biohacking & Longevity: Biohacking is essentially circles back to ancient wellness wisdom (eat well, sleep, exercise)—but enhanced by modern science (measuring phytonutrients, leveraging tech like red light, hyperbaric therapy, protein timing, etc). Emphasizes that “prevention” is still the number one defense against the four top causes of death in Western countries; early proactive screening and lifestyle habits remain critical. There is increasing crossover between “traditional medicine” and “naturopathic”/“functional” approaches—Dr. Gross sees this convergence as positive and overdue, but notes resistance still exists in mainstream medicine. Emerging Business Opportunities in the Wellness Space: IV centers, cryotherapy, and retail biohacking clinics (hyperbaric O2, red light therapy, peptides, weight loss clinics, etc.) are booming, especially in health-conscious cities. Low-barrier options: health coaching, nutrition consulting, affiliate/online influencer businesses—Dr. Gross notes people he knows personally earning seven figures as wellness affiliates. Innovations: Short-form EMS (electro-muscular stimulation) workouts, “blood flow restriction” exercise systems, and more. Cancer screening clinics: Now possible with advanced genomics and blood-testing—these are in demand but not widely available through traditional doctors/insurance, opening more avenues for direct-to-consumer providers. Supplementation & Biohacking Basics: “Non-negotiables” for almost everyone: Vitamin D3 (& often K2): Most people are deficient; optimal blood levels promote longevity, reduce inflammation, and lower all-cause mortality. Magnesium: Especially at night for recovery and cellular repair. Creatine: Improves muscle mass, heart health, and brain health; well correlated with longevity. Probiotics: Modern lifestyles make gut health challenging—good probiotic support is important. Nicotine: Can be a cognitive enhancer in low doses and proper delivery (gum/patch, NOT smoking)—but is highly addictive. Other Business/Money Ideas: Successful affiliate and influencer businesses for those passionate about health and wellness. Emphasizes supplement sales (with high trust and real value), personalized coaching, and education are evergreen opportunities. Industry Critique: Criticizes health insurance as a “legal mafia,” noting it often adds cost and hassle while limiting real preventive care. Encourages listeners to be their “own best advocate” for health—don't rely only on five-minute mainstream doctor visits. Connect with Dr. Jeff Gross: https://recellebrate.com/
© 2020-2025 Ivy Podcast Discovery LLC
